Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6443856 | 1.00 | LMNA (0.64) | LMNAPOLBALDH1A1NPSR1MEN1 | |
| SCHEMBL4669286 | 1.00 | LMNA (0.64) | LMNAPOLBALDH1A1NPSR1MEN1 | |
| SCHEMBL8460521 | 0.94 | LMNA (0.57) | LMNAPOLBALDH1A1 | |
| SCHEMBL1469483 | 0.84 | LMNA (0.68) | LMNAPOLBALDH1A1NPSR1MEN1 | |
| SCHEMBL6945700 | 0.82 | ALDH1A1 (0.67) | LMNAPOLBALDH1A1NPSR1 | |
| SCHEMBL5078328 | 0.82 | LMNA (0.57) | LMNAPOLBALDH1A1NPSR1 | |
| SCHEMBL25323826 | 0.81 | LMNA (0.70) | LMNAPOLBALDH1A1NPSR1 | |
| SCHEMBL8845308 | 0.81 | LMNA (0.64) | LMNAPOLBALDH1A1NPSR1MEN1 | |
| SCHEMBL10290385 | 0.81 | LMNA (0.64) | LMNAPOLBALDH1A1NPSR1MEN1 | |
| SCHEMBL23049101 | 0.81 | LMNA (0.64) | LMNAPOLBALDH1A1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | LMNA 1225/4885POLB 1584/4885ALDH1A1 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.